Pharmacogenomics最新文献_第8页

Relevance of NAT2 genotype and clinical factors to risk for antituberculosis drug-induced liver injury. NAT2 基因型和临床因素与抗结核药物诱发肝损伤风险的相关性。

IF 2.1 4区医学

Pharmacogenomics Pub Date : 2024-01-01 Epub Date: 2023-12-22 DOI: 10.2217/pgs-2023-0148

Fang Cheng, Chao-Chao Qiu, Xian-Gao Jiang, Te Wu, Qiang Zhang, Xin Chen, Shi-Lin Zheng, Sai-Duo Liu, Xin-Chun Ye, Ji-Chan Shi

引用次数: 0

Update on HLA-B*15:02 allele associated with adverse drug reactions. 与药物不良反应相关的 HLA-B*15:02 等位基因的最新进展。

IF 2.1 4区医学

Pharmacogenomics Pub Date : 2024-01-01 Epub Date: 2024-02-02 DOI: 10.2217/pgs-2023-0173

Xueting Zhu, Guanghua Luo, Lu Zheng

引用次数: 0

Potential association of SULT2A1 and ABCG2 variant alleles with increased risk for palbociclib toxicity. SULT2A1和ABCG2变异等位基因与帕博西尼毒性风险增加的潜在关联。

IF 1.9 4区医学

Pharmacogenomics Pub Date : 2024-01-01 Epub Date: 2024-08-02 DOI: 10.1080/14622416.2024.2380240

Chong Wang, Mary Hwang, Brandon Paulson, Doreen Mhandire, Sadat Ozair, Tracey L O'Connor, Shipra Gandhi, Kristopher M Attwood, Daniel L Hertz, Andrew Kl Goey

{"title":"Potential association of SULT2A1 and ABCG2 variant alleles with increased risk for palbociclib toxicity.","authors":"Chong Wang, Mary Hwang, Brandon Paulson, Doreen Mhandire, Sadat Ozair, Tracey L O'Connor, Shipra Gandhi, Kristopher M Attwood, Daniel L Hertz, Andrew Kl Goey","doi":"10.1080/14622416.2024.2380240","DOIUrl":"10.1080/14622416.2024.2380240","url":null,"abstract":"Aim: This study evaluated associations between CYP3A4*22 and variants in other pharmacogenes (CYP3A5, SULT2A1, ABCB1, ABCG2, ERCC1) and the risk for palbociclib-associated toxicities.Materials & methods: Two hundred cancer patients who received standard-of-care palbociclib were genotyped and associations with toxicity were evaluated retrospectively.Results: No significant associations were found for CYP3A4*22, CYP3A5*3, ABCB1_rs1045642, ABCG2_rs2231142, ERCC1_rs3212986 and ERCC1_rs11615. Homozygous variant carriers of SULT2A1_rs182420 had higher incidence of dose modifications due to palbociclib toxicity (odds ratio [OR]: 4.334, 95% CI: 1.057-17.767, p = 0.042). ABCG2_rs2231137 variant carriers had borderline higher incidence of grade 3-4 neutropenia (OR: 4.14, 95% CI: 0.99-17.37, p = 0.052).Conclusion: Once validated, SULT2A1 and ABCG2 variants may be useful to individualize palbociclib dosing to minimize toxicities and improve treatment outcomes.","PeriodicalId":20018,"journal":{"name":"Pharmacogenomics","volume":" ","pages":"367-375"},"PeriodicalIF":1.9,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11418216/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141875602","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Evaluation of pharmacogenetic automated clinical decision support for clopidogrel. 评估氯吡格雷的药物基因自动临床决策支持。

IF 1.9 4区医学

Pharmacogenomics Pub Date : 2024-01-01 Epub Date: 2024-09-11 DOI: 10.1080/14622416.2024.2394014

Amanda Massmann, Joel Van Heukelom, Max Weaver, April Schultz, Debbie M Figueroa, Adam Stys, Tomasz P Stys, Kurt D Christensen

{"title":"Evaluation of pharmacogenetic automated clinical decision support for clopidogrel.","authors":"Amanda Massmann, Joel Van Heukelom, Max Weaver, April Schultz, Debbie M Figueroa, Adam Stys, Tomasz P Stys, Kurt D Christensen","doi":"10.1080/14622416.2024.2394014","DOIUrl":"10.1080/14622416.2024.2394014","url":null,"abstract":"Aim: Clopidogrel requires CYP2C19 activation to have antiplatelet effects. Pharmacogenetic testing to identify patients with impaired CYP2C19 function can be coupled with clinical decision support (CDS) alerts to guide antiplatelet prescribing. We evaluated the impact of alerts on clopidogrel prescribing.Materials & methods: We retrospectively analyzed data for 866 patients in which CYP2C19-clopidogrel CDS was deployed at a single healthcare system during 2015-2023.Results: Analyses included 2,288 alerts. CDS acceptance rates increased from 24% in 2015 to 63% in 2023 (p < 0.05). Adjusted analyses also showed higher acceptance rates when clopidogrel had been ordered for a percutaneous intervention (OR: 28.7, p < 0.001) and when cardiologists responded to alerts (OR: 2.11, p = 0.001).Conclusion: CDS for CYP2C19-clopidogrel was effective in reducing potential drug-gene interactions. Its influence varied by clinician specialty and medication indications.","PeriodicalId":20018,"journal":{"name":"Pharmacogenomics","volume":"25 8-9","pages":"391-399"},"PeriodicalIF":1.9,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11418215/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142293125","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Estimated clinical utility of multi-gene pharmacogenetic testing in a retrospective cohort of gynecology patients. 妇科病人回顾性队列中多基因药物基因检测的临床效用估计。

IF 1.9 4区医学

Pharmacogenomics Pub Date : 2024-01-01 Epub Date: 2024-11-15 DOI: 10.1080/14622416.2024.2428585

Glenda Hoffecker, Karl Keat, Lakeisha Mulugeta-Gordon, Marjorie Risman, Shefali S Verma, Mary Deagostino-Kelly, Sony Tuteja

{"title":"Estimated clinical utility of multi-gene pharmacogenetic testing in a retrospective cohort of gynecology patients.","authors":"Glenda Hoffecker, Karl Keat, Lakeisha Mulugeta-Gordon, Marjorie Risman, Shefali S Verma, Mary Deagostino-Kelly, Sony Tuteja","doi":"10.1080/14622416.2024.2428585","DOIUrl":"10.1080/14622416.2024.2428585","url":null,"abstract":"Objective: This study aimed to estimate the clinical utility of performing multi-gene pharmacogenetic testing on patients undergoing gynecologic surgery/procedure by evaluating the prescribing rate of Clinical Pharmacogenetics Implementation Consortium (CPIC) level A medications and frequency of drug-gene interactions (DGIs).Methods: The electronic health record was queried for 76 current procedural terminology codes to identify gynecologic surgeries/procedures that occurred between 1 January 2015 to 31 December 2020 in patients with at least one of 152 international classification of disease codes. Prescription data for CPIC level A medications was extracted. Those enrolled in the Penn Medicine Biobank were assessed for DGIs.Results: The cohort consisted of 7798 female patients and 682 were in the biobank. Up to 6 years following their surgery or procedure, 80% were ordered ≥1 CPIC level A medication. Over half (54%) of these medications were ordered within 3 days after their surgery or procedure. The most common CPIC level A medications ordered were ibuprofen (57%) and ondansetron (42%). Overall, 7% of the cohort had ≥1 known or predicted DGI with medications they were prescribed.Conclusion: Multi-gene pharmacogenetic testing may be beneficial to gynecologic surgery/procedure patients by assisting clinicians with prescribing postoperative analgesics and future medications.","PeriodicalId":20018,"journal":{"name":"Pharmacogenomics","volume":" ","pages":"587-594"},"PeriodicalIF":1.9,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11703490/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142639447","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Hydroxychloroquine-induced acute generalized exanthematous pustulosis with HLA-typing. 羟氯喹诱发的急性全身泛发性脓疱病伴有 HLA-分型。

IF 1.9 4区医学

Pharmacogenomics Pub Date : 2024-01-01 Epub Date: 2024-11-18 DOI: 10.1080/14622416.2024.2430167

Qiaoli Zheng, Na Jin, Hao Cheng

引用次数: 0

Update on the PriME-PGx initiative: evolution of pharmacogenetics in daily clinical practice. PriME-PGx 计划的最新进展：药物遗传学在日常临床实践中的发展。

IF 1.9 4区医学

Pharmacogenomics Pub Date : 2024-01-01 Epub Date: 2024-08-08 DOI: 10.1080/14622416.2024.2375188

Eva González-Iglesias, Francisco Abad-Santos

引用次数: 0

Real-world evaluation of CYP2C19 guided antiplatelet therapy in patients undergoing intracranial aneurysm repair. 对接受颅内动脉瘤修补术的患者进行 CYP2C19 指导的抗血小板疗法的真实世界评估。

IF 1.9 4区医学

Pharmacogenomics Pub Date : 2024-01-01 Epub Date: 2024-10-03 DOI: 10.1080/14622416.2024.2406213

Layna P Fox, Kayla R Tunehag, Anh Nguyen, Samuel Reed, Darshan Shastri, Nathan Quig, George A Stouffer, Sten Solander, Craig R Lee

{"title":"Real-world evaluation of CYP2C19 guided antiplatelet therapy in patients undergoing intracranial aneurysm repair.","authors":"Layna P Fox, Kayla R Tunehag, Anh Nguyen, Samuel Reed, Darshan Shastri, Nathan Quig, George A Stouffer, Sten Solander, Craig R Lee","doi":"10.1080/14622416.2024.2406213","DOIUrl":"10.1080/14622416.2024.2406213","url":null,"abstract":"Aim: To evaluate the feasibility and impact of using CYP2C19 genotype to guide selection of antiplatelet therapy in patients undergoing intracranial aneurysm treatment with a flow diversion stent in a real-world clinical setting.Patients & methods: A single-center, retrospective, observational cohort study was conducted in 112 patients undergoing intracranial aneurysm repair with flow-diversion stenting from 2014 to 2021. Data were abstracted from health records. The frequency of clopidogrel or alternative therapy (ticagrelor or prasugrel) use was compared across CYP2C19 status (intermediate or poor metabolizer [IM/PM] vs. normal, rapid, or ultrarapid metabolizer [NM/RM/UM]).Results: In the study population, CYP2C19 genotype testing was performed on 110 (98.2%) patients; of these, 106 (97.2%) had results available prior to the stent procedure and 28 (25.5%) were IM/PMs. Alternative therapy was used more frequently in IM/PMs compared with NM/RM/UMs (57.1 vs. 8.5%, respectively, p < 0.0001). The frequency of thromboembolic events over 12 months did not significantly differ across clopidogrel-treated IM/PMs, clopidogrel-treated NM/RM/UMs and patients on alternative therapy (p = 0.352); although, event numbers were low.Conclusion: A pre-emptive CYP2C19 genotyping strategy to guide antiplatelet therapy selection in intracranial aneurysm repair patients is feasible in a real-world clinical setting. Larger studies are needed to assess the impact on clinical outcomes.","PeriodicalId":20018,"journal":{"name":"Pharmacogenomics","volume":" ","pages":"503-513"},"PeriodicalIF":1.9,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11760749/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142366213","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Analysis of the current situation of pharmacogenomics in terms of educational and healthcare needs in Egypt and Lebanon. 从埃及和黎巴嫩的教育和医疗需求角度分析药物基因组学的现状。

IF 1.9 4区医学

Pharmacogenomics Pub Date : 2024-01-01 Epub Date: 2024-10-09 DOI: 10.1080/14622416.2024.2403967

Sahar M El-Gowilly, Heba A Metwaly, Dalia Makhlouf, Nehal Elmansoury, Salwa A Abuiessa, Amani A Sorour, Mohamed Hussein Abdelgalil, Mirna Fawaz, Asmaa M Abushady, Mariam Gamaleldin, Tarek M Abdelghany, Rajaa Fakhoury, Rasha Abdelhady, Amal Mh Ghanim, Samah Shehata, Marwa Kamal, Rehab Bahy, Sanaa A Haroon, Vangelis G Manolopoulos, Ingolf Cascorbi, Ann Daly, Noha F Abdelkader, Said El Shamieh, Mohamed Nagy, Ahmed Wahid

{"title":"Analysis of the current situation of pharmacogenomics in terms of educational and healthcare needs in Egypt and Lebanon.","authors":"Sahar M El-Gowilly, Heba A Metwaly, Dalia Makhlouf, Nehal Elmansoury, Salwa A Abuiessa, Amani A Sorour, Mohamed Hussein Abdelgalil, Mirna Fawaz, Asmaa M Abushady, Mariam Gamaleldin, Tarek M Abdelghany, Rajaa Fakhoury, Rasha Abdelhady, Amal Mh Ghanim, Samah Shehata, Marwa Kamal, Rehab Bahy, Sanaa A Haroon, Vangelis G Manolopoulos, Ingolf Cascorbi, Ann Daly, Noha F Abdelkader, Said El Shamieh, Mohamed Nagy, Ahmed Wahid","doi":"10.1080/14622416.2024.2403967","DOIUrl":"10.1080/14622416.2024.2403967","url":null,"abstract":"Pharmacogenomics (PGx) is a practice that investigates the link between genetic differences and drug response in patients. This can improve treatment effectiveness and reduce harmful side effects. However, has yet to be adequately realized in developing nations. Three surveys were conducted between November 2022 to March 2023 in Egypt and Lebanon. The first survey assessed availability of PGx testing in different healthcare facilities; the second one assessed knowledge, interest and attitude toward learning about PGx among pharmacists and physicians; and the third one assessed interest in providing PGx education at academic levels. In Egypt, a few of the surveyed healthcare facilities are conducting some form of pharmacogenetic testing. In Lebanon, very few germline pharmacogenomic tests are offered in Greater Beirut's leading hospitals, and no other testing was recorded. PGx education attracts considerable interest, with 34.3% of pharmacists very interested and 48.8% interested. Similarly, 24.8% of total physicians were very interested while 44.8% were interested. Academic professionals in the surveyed institutions in both countries agreed on the need for educational programs in PGx and 78.2% agreed that there were good opportunities for implementing PGx testing. These findings clearly indicate the need to develop and implement educational programs in PGx in the Middle-East.","PeriodicalId":20018,"journal":{"name":"Pharmacogenomics","volume":" ","pages":"429-440"},"PeriodicalIF":1.9,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11492645/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142392332","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Antiplatelet therapy guided by CYP2C19 point-of-care pharmacogenetics plus multidimensional treatment decisions. 以 CYP2C19 床旁药物遗传学为指导的抗血小板疗法加上多维治疗决策。

IF 2.1 4区医学

Pharmacogenomics Pub Date : 2024-01-01 Epub Date: 2024-01-17 DOI: 10.2217/pgs-2023-0200

Victor Voicu, Nicolas Diehm, Igal Moarof, Sarah Parejo, Florent Badiqué, Andrea Burden, David Niedrig, Markus Béchir, Stefan Russmann

引用次数: 0